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Expression of anti-Z-DNA single chain
antibody variable fragment on the
filamentous phage surface





We describe the expression of an anti-Z-DNA single chain variable
region antibody fragment (scFv) on a filamentous phage surface. Four
vectors for phage display were constructed. Two of them are able to
display multiple copies of the antibody fragment, and the others can be
used to make monovalent libraries. The vectors use different pro-
moter/leader sequences to direct the expression of the fused proteins.
All were able to promote the assembly of fusion virion particles. In this
paper we also show the affinity selection (biopanning) of those phage-
antibodies based on the capacity of their products to recognize the
antigen. We used biotinylated Z-DNA and the selection was per-
formed in a solution phase fashion. The data presented here indicate
that these vectors can be further used to construct anti-nucleic acid
antibody fragment libraries that can be used to study the basis of
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Anti-Z-DNA antibodies are found in se-
rum of patients with autoimmune diseases
such as systemic lupus erythematosus and
rheumatoid arthritis (1). It is also possible to
induce them by immunization with Br-(dG-
dC)n, a stable Z-DNA conformation polymer
(2). Thus, the study of the basis of nucleic
acid recognition by this kind of antibodies
can provide insights into the structural rela-
tionship between autoantibodies and vacci-
nal antibodies to this class of antigens. These
studies must include the production of mu-
tant forms of those antibodies and measure-
ment of their residual affinity/specificity.
An important technology that arose in
1988 for studying macromolecular interac-
tions is the display of foreign proteins and
peptides on the surface of filamentous phages
(3). This technique permits the generation of
libraries of molecules with affinities for cer-
tain ligands, and when it is associated with
biopanning and selection, new high-affinity
forms can be isolated. Antibodies (particu-
larly their Fvs - variable fragment and/or
Fabs - antigen binding fragments) are the
most common biomolecules expressed on
the filamentous phage surface. The associa-
tion of phage display libraries with biopan-
ning can mimic the immune system clonal
selection (4). The development of the anti-
body display on the filamentous surface has
been the subject of extensive investigations
(for a more extensive review, see Ref. 5).
Using this approach it was possible to isolate
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new high-affinity antibody forms (4,6), or
even change specifities of well-character-
ized ones (7,8).
Phage display libraries are usually as-
sembled in two different kinds of vectors.
The initial studies were done using phage
vectors derived from the filamentous phage
genome, such as fd, f1 and M13 (9). More
recently, the literature has proposed the use
of phagemid vectors containing the filamen-
tous phage intergenic region that comprises
the rolling circle phage origin of replication
which enables it to pack into the fusion
virion particle (10). This last type of vector is
used to transform the F+ host strain and the
library can be rescued by helper phage (11).
The advantage of using phagemids is the
easier manipulation of a plasmid DNA over
a phage genome that facilitates cloning and
DNA preparation.
A phagemid to be used for phage display
library purposes must have some specific
features. First, it should be able to produce
N-terminal fusion molecules (library) with
one of the phage coat protein. Usually, the
most common are protein VIII, the major
coat protein (pVIII), and protein III, one of
the proximal end protein responsible for vi-
rus infectivity (pIII). For this purpose, a leader
sequence (for secretion) and a weak pro-
moter always precede the fusion system.
Besides these characteristics, a phagemid
must have a selection marker (to allow selec-
tion of the transformed strains) and both
bacterial and viral replication origins (12).
The choice of gene VIII or III fusion is
based on the experimental hypothesis ad-
dressed. Since gene VIII expresses the major
coat protein, the fusion molecule with pro-
tein VIII is displayed on the virion surface in
multiple copies, so the selection is also a
function of the avidity of these repeated
molecules. These libraries are called poly-
or multivalent (13). If the choice is to con-
struct a monovalent library, the fusion virion
partner should be protein III since each virion
has 5 to 6 copies of them (14) and the fusion
particle would display 1 to 3 fusion mol-
ecules (13). Recent studies have proposed
the use of multivalent libraries for initial
screening experiments and in a second step,
when refined ligands are desired, the monova-
lent libraries would be the choice (15).
In this paper we describe the display of
an anti-Z-DNA antibody fragment (scFv) on
the filamentous bacteriophage surface in a
mono- or multivalent fashion. To produce
these fusion particles we have constructed
two new vectors and modified a third one to
construct two additional ones. We also show
that the particles that display anti-Z-DNA
are selected by the interaction with biotinyl-
ated Z-DNA. This study represents the first
step in identifying the amino acid residues
that play an important role in the nucleic acid
recognition by antibodies.
Material and Methods
Construction of pAIg 316 and 816 vectors
Multistep construction was carried out
using standard molecular biology techniques
(16). pAIg 316 was constructed in two steps:
initially, the M13 gene III was amplified by
PCR using a pair of primers (5’ GCCCATGG
CTCCGGTACCGGTACCGAAACTGTTGAA
AGTTG 3’ and 5’ GCGAATTCTGGCATGA
TTAAGACTC 3’) designed to generate a
fragment of 1.2 kb, encoding the mature
form of pIII and flanked by NcoI and EcoRI
restriction sites. The design was performed
based on M13 mp18 sequence data obtained
from the gene bank (access number X02513).
The PCR product was digested with both
restriction endonucleases and cloned into
pIg 16, a vector that codes for the scFv
fragment of the anti-Z-DNA Z22 antibody
(17). This vector was named pIg 316. The
next step was transfer the fusion (scFv/gene
III) to the pGEM 3Z (f-) phagemid
(Promegaâ, Madison, WI, USA). The recipi-
ent plasmid and the donor were digested
with XmaI and EcoRI, and the fusion frag-
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ment was ligated to pGEM 3z phagemid,
giving origin to phagemid pGIg 316. The
protein A promoter and leader sequence
(PPLA) was initially obtained from the pGTT
15 plasmid (18) by PCR and subsequently
digested with BclI and HindIII endonucleases.
The sequences of the primers used were 5’
GATTTAGGTGACACTATAG 3’ and 5’
CGCCCGGGCTTTTGTCACAGG 3’ for the
amplification of the promoter/leader se-
quence from upstream sequences and car-
boxyl terminus, respectively. The PPLA frag-
ment was cloned into pGIg 316 BamHI and
HindIII unique sites, giving origin to phage-
mid pAIg 316, which is able to express Z22
scFv fused with pIII. Phagemid pAIg 816
was constructed by replacing the pAIg 316
gene III with gene VIII. Gene VIII was ob-
tained by PCR, using a pair of primers (5’
CCCATGGCTCCGGTACCGCTGAGGGT
GACGAT 3’ and 5’ GAGCCTTGAATTCTA
TCGGTTTATC 3’) designed to amplify the
mature portion of the M13 pVIII gene (ap-
proximately 150 bp), flanked by NcoI and
EcoRI restriction sites. The primers were
designed based on the same sequence as
described above (access number X02513).
The PCR product was ligated to the pAIg 316
vector gene III-less fragment, and the resulting
phagemid was called pAIg 816. The two vec-
tors were checked by nucleotide sequencing
of the fusion regions: leader sequence/scFv
and scFv/gene III and VIII.
Construction of pCIg 316 and 816 vectors
Phagemids named pCIg were derived
from the pCANTAB 5E Pharmaciaâ vector
(Uppsala, Sweden). To construct these vec-
tors the linear recipient plasmid pCANTAB
5E was ligated to a DNA linker, harboring
XmaI, BglII, XbaI and NcoI restriction sites,
giving rise to the pCL vector. The oligo-
nucleotides used to make the synthetic linker
showed the following sequences: 5’ CGGC
CCGGGAAGATCTCTAGATCCCATGG
TGC 3’ and 5’ GGCCGCACCATGGGATCT
AGAGATCTTCCCGGGCCG 3’. The an-
nealing procedure was performed by mixing
equimolar quantities of both oligonucle-
otides, heating them and allowing them to
cool down to room temperature under high
salt conditions. The annealed linker harbors
cohesive ends (NotI and SfiI) that permit it to
ligate to linearized pCANTAB 5E. The pCL
vector was digested with XmaI and NcoI and
ligated to the scFv fragment isolated from
pGIg 316, giving origin to pCIg 316. Phage-
mid pCIg 816 was obtained by replacing the
pCIg 316 gene III with gene VIII (the same
used to construct pAIg 816), that was cloned
into the pGEM-T vector, showing NcoI and
EcoRI restriction sites. As a negative control
for fusion protein production, the pCIg 16
plasmid was also constructed from pCL,
introducing the fusion scFv/protein A from
the pIg 16 vector instead of scFv/gene III or
VIII at the same sites, XmaI and EcoRI. This
last vector (pCIg 16) produces soluble Z22
scFv without a phage protein partner. The
constructions were checked by nucleotide
sequencing, mainly in their fusion regions:
scFv/gene III or VIII.
Phage production and panning
Fusion phage particles were produced,
titrated and selected using a protocol modi-
fied from the Recombinant Phage Selection
Module (Pharmaciaâ). Briefly, transformed
E. coli cells (strain TG1) were inoculated
into 2X YT medium containing 2% glucose.
The cultures were incubated at 37oC with
shaking at 250 rpm until they reached an
A600 of 0.5. At this point ampicillin was
added to a final concentration of 100 µg/ml
and 3 x 1010 plaque-forming units of helper
phage M13K07. The cultures were incu-
bated for 1 h under the same conditions and
then spun at 3,000 g for 10 min to sediment
the cells. The cell pellets were resuspended
in 2X YT medium containing ampicillin (100
µg/ml) and kanamycin (50 µg/ml) and incu-
bated overnight at 37oC with shaking at 250
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rpm. The supernatants, containing fusion
phages, were obtained by centrifuging the
cell cultures at 3,000 g for 20 min. The phage
preparations were titrated to determine the
yield of ampicillin-transducing units per mil-
liliter for each construction. These proce-
dures were carried out by infecting log-phase
E. coli TG1 cells with serial supernatant
dilutions. A typical phage yield obtained
was 1010 to 1011 ampicillin-transducing units/
ml. The amount of transducing units used for
solution phase selection was 3 to 4 x 1010 for
each construction. In this experiment we
used transducing units from all five con-
structions: pAIg 316, pAIg 816, pCIg 316,
pCIg 816 and also pCIg 16 (virion particle
without fusion protein) as a negative control.
The selection procedure was performed
in a final volume of 1.4 ml containing the
phage suspension diluted in PBS, blocking
buffer (280 µl of 10% nonfat milk) and
biotinylated Z-DNA (7 µl of a stock solution
of 66 µg/ml prepared as described in Ref.
17). Initially, the fusion phage suspension
was incubated with blocking buffer for 10
min followed by incubation with the antigen
for 1 h at room temperature, with gentle
rocking on a shaker table. At this point 60 µl
of resuspended streptavidin-agarose resin
was added and further incubated for 20 to 60
min under the same conditions. The samples
were spun at 1,000 g for 1 min and the
supernatant was removed. The pellet was
washed 6 times with 0.05% PBS-Tween 20
by discarding the supernatant after centrifu-
gation at 1,000 g. The washed agarose was
transferred to 10 ml of log-phase TG1 E. coli
cells to allow infection. Several dilutions of
the transduced cells were plated onto
SOBAG/ampicillin plates and incubated at
30oC, and the number of individual clones
was determined. After this first round of
selection, additional rounds were also per-
formed. The estimated amount of transduc-
ing units per cycle was determined for each
construction by subtracting the average num-
ber of colonies obtained with transformed
pCIg 16 cells. We used the average number
of pCIg 16 transducing units to represent the
background of nonspecific binding of helper
phage particles.
Results and Discussion
To produce virion particles harboring Z22
scFv we constructed two new vectors and
modified the Pharmacia pCANTAB 5E vec-
tor, creating two new versions of the latter.
Vector pAIg 316 was assembled by ampli-
fying and cloning both virus gene (gene III)
and promoter and leader sequences of the
Staphylococcus aureus protein A gene. Gene
III was obtained from the M13 genome with
the primers described in Material and Meth-
ods. These primers create restriction enzyme
sites (NcoI at the 5’ end and EcoRI at the 3’
end). The 1.2-kb fragment was digested with
both enzymes and cloned into the pIg 16 vec-
tor (17). The whole cassette (scFv/gene III)
was then transferred to the Promega pGEM 3Z
f(-) vector in order to receive the promoter and
leader sequences of the Staphylococcus aureus
protein A gene (fragment PPLA). This new
vector (pGIg 316) was then digested with
HindIII and BamHI to receive the PPLA frag-
ment. This last fragment was obtained by PCR
of the S. aureus protein A gene cloned into the
pGTT 15 vector (18). The PCR fragment was
used instead of the original pGTT 15 to avoid
the inhibitory effect of methylation of the BclI
site. The PCR fragment (1.5 kb) was then
cleaved with HindIII and BclI, giving origin to
a 0.8-kb fragment that was purified and cloned
into linear pGIg 316. This vector was named
pAIg 316 (the whole strategy of construction
of this vector is presented in Figure 1). The
production of the fusion protein was observed
in Southern-Western blot experiments by com-
paring the ability of the fusion and wild type
particles to bind Z-DNA (data not shown).
To construct the pAIg 816 vector (the
strategy is also presented in Figure 1), the
M13 gene VIII was amplified by PCR and
cloned between the NcoI and EcoRI sites of
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Figure 1 - Schematic representation of pAIg vector constructions. The M13 gene III was obtained by PCR with specially designed oligonucleotides (see
Material and Methods) and then transferred to the pIg 16 vector (17). This originated the pIg 316 vector. The whole cassette single chain variable region
antibody fragment (scFv)/gene III was cloned into XmaI and EcoRI sites of the Promega vector pGEM 3Z (f-), giving rise to the pGIg 316 plasmid. The
fragment containing the S. aureus protein A promoter and leader sequence (PPLA) was obtained by PCR and a subsequent digestion with BclI and
HindIII from the pGTT 15 vector (18). This insert was cloned into HindIII and BamHI sites of pGIg 316, originating the pAIg 316 phagemid. To construct
pAIg 816, the M13 gene III was replaced by the M13 gene VIII, which was obtained by PCR with specially designed primers from the M13 genome.
Gene VIII was cloned into NcoI and EcoRI sites.
574
Braz J Med Biol Res 33(5) 2000
A.Q. Maranhão and M.M. Brígido
the gene III-less pAIg 316 phagemid.
The phagemids pCIg 316 and 816 were
constructed from the pCANTAB 5E vector
(Pharmacia). This plasmid is available com-
mercially in linear form. To transfer Z22
scFv to this vector we constructed and cloned
a synthetic linker and the resulting plasmid
was called PCL. Between XmaI and NcoI
PCL restriction sites we cloned the pIg 16
scFv, and this vector was called pCIg 316.
Phagemid pCIg 816 was obtained by replac-
ing pCIg 316 fd gene III with M13 gene VIII
(obtained by PCR as described for pAIg
816). The strategies of these constructions
are schematically presented in Figure 2. As a
negative control, we also constructed pCIg
16, which is a vector that produces soluble
scFv, without a virus partner. Thus, cells
harboring pCIg 16 produce wild type  phage
particles.
The phagemids express a pIII (316) or
pVIII (816) product fused with anti-Z-DNA
scFv. In two of them (pAIgs) the production
of fusion molecules is under the control of
the Staphylococcus aureus protein A pro-
moter and leader sequence, while the other
two (pCIgs) are derived from the pCANTAB
5E Pharmaciaâ vector (which has the pLac-
lactose operon promoter, and the fd phage
gene III leader sequence).
The open reading frame-predicted se-
quences of the fusion proteins are shown in
Figure 3. The nucleotide sequences of all
four vector fusion regions were determined
by sequencing procedures and are highlighted
in the same figure. These determinations
revealed that at least at these regions the
open reading frames, as expected, were able
to produce fusion proteins in a correct frame.
Fusion virion particles were produced by
standard protocols and selected in a solu-
tion-phase assay: phage antibodies were
mixed with biotinylated antigen (Z-DNA)
and the complex was captured from solution
with streptavidin-agarose resin. The washed
streptavidin/biotinylated antigen/phage an-
tibody complex was used to infect log-phase
E. coli TG1 cells which could be rescued
with the helper phage, selected again or plated
onto SOBAG plates. All four vectors were
able to produce phage-displaying scFv, since
it was possible to select them using Z-DNA
as antigen.
The results of three rounds of selection
(Table 1) show a 100- to 10,000-fold in-
crease in transducing units/ml in round 3
when compared with round 1 of selection.
This is expected, since no diversity was in-
troduced in the scFv sequence from one
round to another, so that selection favored
the virion particles able to bind to Z-DNA.
Using these four vectors one would ex-
pect a larger amount of colonies arising from
816 vectors than from 316 vectors due to
their multivalent display of fusion proteins
(19). According to our results, only pCIgs
showed this feature: in round 3 we obtained
about 20 times more transducing units/ml
using pCIg 816 than using pCIg 316. The
data for the pAIg vectors did not show this
behavior; in fact pAIg 316 yielded 5 times
more transducing units/ml than pAIg 816.
This discrepancy may be the result of the
expression level driven by two different pro-
moters. The staphylococcal promoter (pAIg
vectors) is a constitutive promoter while pLac
(pCIg vectors) is an inducible one. In our
experimental procedure for phage produc-
tion we used a condition of no induction of
pLac (medium without inductor), so that the
expression of scFv/pIII or pVIII is a result of
basal pLac expression, and, in this situation,
the expression is considered to be weak (20).
On the other hand, Escherichia coli cells
harboring the original protein A expression
vector, pGTT 15, express a constitutively
significant amount of this staphylococcal
protein (data not shown). Perhaps the ex-
pression driven by this promoter/leader se-
quence is high enough to affect virus pro-
duction (21). Another aspect that should be
considered is that our scFv-phage was se-
lected against Z-DNA, which is a monoto-
nous molecule, with repeated epitopes (22).
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Figure 2 - Schematic representation of pCIg vector constructions. The Pharmacia pCANTAB 5E vector was modified to express the Z22 single chain
variable region antibody fragment (scFv) fusioned with fd gene III. This commercial vector is available in a linear fashion. To clone the scFv, we
designed self-annealed oligonucleotides to create a linker (see Material and Methods). The annealed oligonucleotides were cloned into the pCANTAB
5E vector, giving rise to the pCL plasmid. The scFv was obtained from the pIg 16 vector (17). This cloning procedure originated the pCIg 316 vector. To
construct pAIg 816, fd gene III was replaced by M13 gene VIII, which was obtained by PCR with specially designed primers from the M13 genome.
Gene VIII was cloned into the NcoI and EcoRI sites, giving rise to the pCIg 816 phagemid.
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Figure 3 - Open reading frame
and predicted fusioned polypep-
tides coded by phage display
vectors. A, Open reading frame
and amino acid prediction of
scFv-M13 gene VIII fusion
cloned into pAIg 816 vector. The
non-coding sequence of PPLA
fragment is in lower case. The
restriction sites used for the
cloning procedure are shown.
The underlined nucleotides
were checked by sequencing
procedures. These regions were
also sequenced for the other
three vectors. B, Open reading
frame of M13 gene III amplified
by PCR from the M13 genome.
The introduced sites are shown.
C, Sequence of the pLac and fd
gene III leader sequence of pCIg
vectors. The introduced XmaI
site is shown. This restriction
site was used to clone Z22 anti-
Z-DNA scFv. The non-coding re-
gion of pLac is in lower case.
A
tta aat tta att ata aat atg att tta gta ttg caa tac ata att cgt tat att atg atg 
act tta caa ata cat aca ggg ggt att aat TTG AAA AAG AAA AAA ATT TAT TCA ATT CGT 
                                        M   K   K   K   K   I   Y   S   I   R   
AAA CTA GGT GTA GGT ATT GCA TCT GTA ACT TTA GGT ACA TTA CTT ATA TCT GGT GGC GTA 
K   L   G   V   G   I   A   S   V   T   L   G   T   L   L   I   S   G   G   V   
ACA CCT GCT GCA AAT GCT GCG CAA CAC GAT GAA GCT CAA CAA AAT GCT TTT TAT CAA GTG 
T   P   A   A   N   A   A   Q   H   D   E   A   Q   Q   N   A   F   Y   Q   V   
                                       I
TTA AAT ATG CCT AAC  
L   N   M   P   N   L   N   A   D   P   R   V   Q   L   V   E   S   G   G   G   
L   V   Q   P   K   G   S   L   K   L   S   C   A   A   S   G   F   N   F   N   
T TTG GAA TGG GTT GCT CGC 
T   Y   A   M   N   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   R   
ATA AGA AGT AAA AGT AAT AAT TAT GCA ACA TAT TAT GCC GAT TCA ATG AAA GAC AGA TTC 
I   R   S   K   S   N   N   Y   A   T   Y   Y   A   D   S   M   K   D   R   F   
ACC ATC TCC AGA GAT GAT TCA GAA AAC ATG CTC TAT CTG CAA ATG ATC AAC TTG AAA GCT 
T   I   S   R   D   D   S   E   N   M   L   Y   L   Q   M   I   N   L   K   A   
GAG GAC ACA GCC ATG TAT TAC TGT GTG AGA CAG GCA TAT AGT AAC TAC GGT GCT ATG GAC 
E   D   T   A   M   Y   Y   C   V   R   Q   A   Y   S   N   Y   G   A   M   D   
TAC TGG GGT CAA GGA ATT TCA GTC ACC GTC TCC TCT AGA GGT GGG GGC GGT TCG GGT GGC 
Y   W   G   Q   G   I   S   V   T   V   S   S   R   G   G   G   G   S   G   G   
GGG GGC TCG GGC GGG GGA GGC TCA GAT CTC CAG ATG ACG CAG ACT ACA TCC TCC CTG TCT 
G   G   S   G   G   G   G   S   D   L   Q   M   T   Q   T   T   S   S   L   S   
GCC TCT CTG GGA GAC AGA GTC ACC ATC AGT TGC AGT GCA AGT CAG GGC ATT AGT AAT TAT 
A   S   L   G   D   R   V   T   I   S   C   S   A   S   Q   G   I   S   N   Y   
TTA AAC TGG TAT CAG CAG AAA CCA GAT GGA ACT GTT AAA CTC CTG ATC TAT TAC ACA TCA 
L   N   W   Y   Q   Q   K   P   D   G   T   V   K   L   L   I   Y   Y   T   S   
AGA TTA CAC TCA GGA GTC CCA TCA AGG TTC AGT GGC AGT GGG TCT GGG ACA GAT TAT TCT 
R   L   H   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D   Y   S   
CTC ACC ATC AGC AAC CTG GAA CCT GAA GAT ATT GCC ACT TAT TTT TGT CAG CAG T  
L   T   I   S   N   L   E   P   E   D   I   A   T   Y   F   C   Q   Q   Y   S   
 I
K   F   P   F   T   F   G   S   G   T   K   L   E   I   K   H   H   H   H   H   
G   S   G   T   A   E   G   D   D   P   A   K   A   A   F   N   S   L   Q   A   
C ATT GTC GGC GCA ACT 
S   A   T   E   Y   I   G   Y   A   W   A   M   V   V   V   I   V   G   A   T   
R I
ATC GGT ATC AAG CTG TTT AAG AAA TTC ACC TCG AAA GCA AGC TGA TAA ACC GAT AGA ATT 
I   G   I   K   L   F   K   K   F   T   S   K   A   S   *   * 
C
Xma
                                                                          Nco
                                                                         Eco
TTA AAC GCT GAT CCC CGG GTG CAA CTT GTT GAG TCT GGT GGA GGA
TTG GTG CAG CCT AAA GGG TCA TTG AAA CTC TCA TGT GCA GCC TCT GGA TTC AAC TTC AAT 
ACC TAC GCC ATG AAC TGG GTC CGC CAG GCT CCA GGA AAG GG
AT AGT
AAG TTC CCA TTC ACG TTC GGC TCG GGG ACA AAG TTG GAA ATA AAA CAT CAT CAT CAC CAT 
GGC TCC GGT ACC GCT GAG GGT GAC GAT CCC GCA AAA GCG GCC TTT AAC TCC CTG CAA GCC 
TCA GCG ACC GAA TAT ATC GGT TAT GCG TGG GCG ATG GTT GTT GT
continued on page 577
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   Nco
Eco
I
CAC CAT GGC TCC GGT ACC GAA ACT GTT GAA AGT TGT TTA GCA AAA CCC CAT ACA GAA AAT 
H   H   G   S   G   T   E   T   V   E   S   C   L   A   K   P   H   T   E   N   
TCA TTT ACT AAC GTC TGG AAA GAC GAC AAA ACT TTA GAT CGT TAC GCT AAC TAT GAG GGT 
S   F   T   N   V   W   K   D   D   K   T   L   D   R   Y   A   N   Y   E   G   
TGT CTG TGG AAT GCT ACA GGC GTT GTA GTT TGT ACT GGT GAC GAA ACT CAG TGT TAC GGT 
C   L   W   N   A   T   G   V   V   V   C   T   G   D   E   T   Q   C   Y   G   
ACA TGG GTT CCT ATT GGG CTT GCT ATC CCT GAA AAT GAG GGT GGT GGC TCT GAG GGT GGC 
T   W   V   P   I   G   L   A   I   P   E   N   E   G   G   G   S   E   G   G   
GGT TCT GAG GGT GGC GGT TCT GAG GGT GGC GGT ACT AAA CCT CCT GAG TAC GGT GAT ACA 
G   S   E   G   G   G   S   E   G   G   G   T   K   P   P   E   Y   G   D   T   
CCT ATT CCG GGC TAT ACT TAT ATC AAC CCT CTC GAC GGC ACT TAT CCG CCT GGT ACT GAG 
P   I   P   G   Y   T   Y   I   N   P   L   D   G   T   Y   P   P   G   T   E   
CAA AAC CCC GCT AAT CCT AAT CCT TCT CTT GAG GAG TCT CAG CCT CTT AAT ACT TTC ATG 
Q   N   P   A   N   P   N   P   S   L   E   E   S   Q   P   L   N   T   F   M   
TTT CAG AAT AAT AGG TTC CGA AAT AGG CAG GGG GCA TTA ACT GTT TAT ACG GGC ACT GTT 
F   Q   N   N   R   F   R   N   R   Q   G   A   L   T   V   Y   T   G   T   V   
ACT CAA GGC ACT GAC CCC GTT AAA ACT TAT TAC CAG TAC ACT CCT GTA TCA TCA AAA GCC 
T   Q   G   T   D   P   V   K   T   Y   Y   Q   Y   T   P   V   S   S   K   A   
ATG TAT GAC GCT TAC TGG AAC GGT AAA TTC AGA GAC TGC GCT TTC CAT TCT GGC TTT AAT 
M   Y   D   A   Y   W   N   G   K   F   R   D   C   A   F   H   S   G   F   N   
GAA GAT CCA TTC GTT TGT GAA TAT CAA GGC CAA TCG TCT GAC CTG CCT CAA CCT CCT GTC 
E   D   P   F   V   C   E   Y   Q   G   Q   S   S   D   L   P   Q   P   P   V   
AAT GCT GGC GGC GGC TCT GGT GGT GGT TCT GGT GGC GGC TCT GAG GGT GGT GGC TCT GAG 
N   A   G   G   G   S   G   G   G   S   G   G   G   S   E   G   G   G   S   E   
GGT GGC GGT TCT GAG GGT GGC GGC TCT GAG GGA GGC GGT TCC GGT GGT GGC TCT GGT TCC 
G   G   G   S   E   G   G   G   S   E   G   G   G   S   G   G   G   S   G   S   
GGT GAT TTT GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG GGG GCT ATG ACC GAA AAT GCC 
G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A   M   T   E   N   A   
GAT GAA AAC GCG CTA CAG TCT GAC GCT AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC 
D   E   N   A   L   Q   S   D   A   K   G   K   L   D   S   V   A   T   D   Y   
GGT GCT GCT ATC GAT GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT GGT AAT GGT GCT 
G   A   A   I   D   G   F   I   G   D   V   S   G   L   A   N   G   N   G   A   
ACT GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT CAA GTC GGT GAC GGT GAT AAT TCA 
T   G   D   F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N   S   
CCT TTA ATG AAT AAT TTC CGT CAA TAT TTA CCT TCC CTC CCT CAA TCG GTT GAA TGT CGC 
P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q   S   V   E   C   R   
CCT TTT GTC TTT AGC GCT GGT AAA CCA TAT GAA TTT TCT ATT GAT TGT GAC AAA ATA AAC 
P   F   V   F   S   A   G   K   P   Y   E   F   S   I   D   C   D   K   I   N   
TTA TTC CGT GGT GTC TTT GCG TTT CTT TTA TAT GTT GCC ACC TTT ATG TAT GTA TTT TCT 
L   F   R   G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F   S   
                                                         R I
ACG TTT GCT AAC ATA CTG CGT AAT AAG GAG TCT TAA TCA TGC GAA TTC 
T   F   A   N   I   L   R   N   K   E   S   * 
Figure 3 - continued.
continued on page 578
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This makes this antigen multivalent itself, so
that a single Z-DNA molecule could bind to
more than one phage, masking a multiva-
lence library effect.
The vectors and protocols presented in
this paper suggest a new experimental model
for displaying libraries of anti-Z-DNA scFv.
These vectors may help to investigate the
basis of DNA-protein interaction and could
be useful to generate specificities for nucleic
acid such as those found in patients with
autoimmune disease.
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